Barclays
TELO icon

Barclays’s Telomir Pharmaceuticals TELO Stock Holding History

Barclays’s Portfolio TELO Stock Details TELO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$708 Buy
+553
New +$720 ﹤0.01% 4962
2026
Q1 		– Sell
-2
Closed -$3 – 5519
2025
Q4 		$3 Hold
2
– – ﹤0.01% 5174
2025
Q3 		$3 Sell
2
-3,015
-100% -$4.55K ﹤0.01% 5427
2025
Q2 		$3.77K Sell
3,017
-17,322
-85% -$40K ﹤0.01% 4996
2025
Q1 		$65.7K Sell
20,339
-9,620
-32% -$42K ﹤0.01% 4538
2024
Q4 		$123K Buy
29,959
+22,941
+327% +$108K ﹤0.01% 4535
2024
Q3 		$45.1K Buy
7,018
+5,367
+325% +$26.2K ﹤0.01% 4770
2024
Q2 		$7.94K Buy
+1,651
New +$10.3K ﹤0.01% 4533

Other funds holding TELO

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
CAPTRUST Financial Advisors
CAPTRUST Financial Advisors Raleigh, North Carolina $65.5B AUM 24.25% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
WIA
World Investment Advisors Santa Barbara, California $6.04B AUM 22.7% 1-Year Est. Return

Barclays's TELO Position: Q2 2026 in Review

Barclays opened a new position in Telomir Pharmaceuticals (TELO) in Q2 2026: 553 shares worth $708. The stake represents ﹤0.01% of the portfolio and ranks #4962 among its holdings. This is a return to the name: Barclays previously reported a position in TELO as recently as Q4 2025.

Barclays first reported a position in TELO in Q2 2024 and has held it in 8 quarters since. The position peaked at $123K in Q4 2024. 33 funds tracked by Wall St. Rank hold TELO as of Q2 2026.

  • Barclays held 553 shares of Telomir Pharmaceuticals worth $708 as of Q2 2026.
  • Telomir Pharmaceuticals was a new Barclays position in Q2 2026.
  • Telomir Pharmaceuticals made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #4962 holding.
  • Barclays first reported a position in Telomir Pharmaceuticals in Q2 2024 and has held it in 8 quarters since.
  • Barclays's Telomir Pharmaceuticals position peaked at $123K in Q4 2024.
  • 33 funds tracked by Wall St. Rank held Telomir Pharmaceuticals as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.